Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Yang, Mingzhen ^a   Yuan, Fang ^a   Li, Peng ^a   Chen, Zhongjiao ^a   Chen, An ^a   Li, Shuhui ^a   Hu, Chuanmin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Cisplatin; Interferon regulatory factor 4 binding protein (IBP); p53

Indexed keywords

CISPLATIN; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 4 BINDING PROTEIN; PIFITHRIN ALPHA; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DOWN REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEGATIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864795068     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-54     Document Type: Article

References (44)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
2. Menendez D, Inga A, Resnick MA. Potentiating the p53 network. Discov Med 2010, 10:94-100.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca-a Cancer J Clin 2005, 55:74-108.
4. Lai H, Lin L, Nadji M, Lai S, Trapido E, Meng L. Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol Ther 2002, 1:31-36.
5. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004, 157:247-270.
6. Jerry DJ, Dunphy KA, Hagen MJ. Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cellular Mol Life Sci 2010, 67:1017-1023.
7. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003, 3:21-29.
8. Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008, 283:739-750.
9. Gupta S, Lee A, Hu CM, Fanzo J, Goldberg I, Cattoretti G, Pernis AB. Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly expressed in the immune system. Hum Immunol 2003, 64:389-401.
10. Oka T, Ihara S, Fukui Y. Cooperation of DEF6 with activated Rac in regulating cell morphology. J Biol Chem 2007, 282:2011-2018.
11. Samson T, Will C, Knoblauch A, Sharek L, von der Mark K, Burridge K, Wixler V. Def-6, a guanine nucleotide exchange factor for Rac1, interacts with the skeletal muscle integrin chain alpha 7A and influences myoblast differentiation. J Biol Chem 2007, 282:15730-15742.
12. Gupta S, Fanzo JC, Hu CM, Cox D, Jang SY, Lee AE, Greenberg S, Pernis AB. T cell receptor engagement leads to the recruitment of IBP, a novel guanine nucleotide exchange factor, to the immunological synapse. J Biol Chem 2003, 278:43541-43549.
13. Chen Q, Gupta S, Pernis AB. Regulation of TLR4-mediated signaling by IBP/Def6, a novel activator of Rho GTPases. J Leukoc Biol 2009, 85:539-543.
14. Fanzo JC, Yang W, Jang SY, Gupta S, Chen QZ, Siddiq A, Greenberg S, Pernis AB. Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J Clin Invest 2006, 116:703-714.
15. Subramanian S, West RB, Marinelli RJ, Nielsen TO, Rubin BP, Goldblum JR, Patel RM, Zhu S, Montgomery K, Ng TL, et al. The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol 2005, 206:433-444.
16. Li P, Zhang ZJ, Wang QL, Li SH, Zhang Y, Bian XW, Chen A, Hu CM. The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells. Int Immunopharmacol 2009, 9:1002-1009.
17. Zhang Z, Wang Q, Li P, Zhou Y, Li S, Yi W, Chen A, Kong P, Hu C. Overexpression of the Interferon regulatory factor 4-binding protein in human colorectal cancer and its clinical significance. Cancer Epidemiol 2009, 33:130-136.
18. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002, 18:333-334.
19. Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, Alba MM, Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Research 2003, 31:3651-3653.
20. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1:45-49.
21. Jordan JJ, Menendez D, Inga A, Nourredine M, Bell D, Resnick MA. Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53. Plos Genetics 2008, 4:e1000104.
22. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
23. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
24. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R. Transcriptional Regulation of Estrogen Receptor-alpha by p53 in Human Breast Cancer Cells. Cancer Res 2009, 69:3405-3414.
25. Moll UM, Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, Pan HG, Kessler H, Pancoska P. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006, 281:8600-8606.
26. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-251.
27. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
28. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982.
29. Sivalenka RR, Sinha M, Jessberger R. SWAP-70 regulates mast cell Fc epsilon RI-mediated signaling and anaphylaxis. Eur J Immunol 2008, 38:841-854.
30. Zheng Y, Guo FK, Gao Y, Wang L. P19(Arf)-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 2003, 278:14414-14419.
31. Bosco EE, Ni WJ, Wang L, Guo FK, Johnson JF, Zheng Y. Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. Blood 2010, 115:3320-3328.
32. Jordan JJ, Menendez D, Inga A, Nourredine M, Bell D, Resnick MA. Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53. Plos Genet 2008, 4:e1000104.
33. Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci USA 2010, 107:1500-1505.
34. Wang B, Xiao ZW, Ren EC. Redefining the p53 response element. Proc Natl Acad Sci USA 2009, 106:16890-16890.
35. Srougi MC, Burridge K. The Nuclear Guanine Nucleotide Exchange Factors Ect2 and Net1 Regulate RhoB-Mediated Cell Death after DNA Damage. Plos One 2011, 6:e17108.
36. Wang L, Yang L, Debidda M, Witte D, Zheng Y. Cdc42 GTPase-activating protein deficiency promotes genomic instability and premature aging-like phenotypes. Proc Natl Acad Sci USA 2007, 104:1248-1253.
37. Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S. Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta 2004, 1705:103-120.
38. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level (review). Oncol Rep 2003, 10:1663-1682.
39. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008, 122:534-546.
40. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38 alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
41. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, Galeotti T. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 2006, 25:3689-3698.
42. Ozaki M, Haga S, Zhang HQ, Irani K, Suzuki S. Inhibition of hypoxia/reoxygenation-induced oxidative stress in HGF-stimulated antiapoptotic signaling: role of P13-K and Akt kinase upon rac1. Cell Death Differ 2003, 10:508-515.
43. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
44. Li C, Chen H, Ding F, Zhang Y, Luo A, Wang M, Liu Z. A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J 2009, 422:363-372.